Injectable matrix metalloproteinase-responsive nanoparticle hydrogel scaffold for sustained local drug delivery in fibrous dysplasia
Open Access
- 28 May 2026
- journal article
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
Abstract
RANKL inhibition has shown significant therapeutic benefit in fibrous dysplasia (FD). However, sustained RANKL inhibition is required to maintain its therapeutic effect. Moreover, disease rebound following discontinuation of denosumab, a human monoclonal RANKL antibody, poses a major clinical challenge to FD treatment, thereby highlighting the need for strategies that preserve lesion-level efficacy while limiting systemic exposure. Matrix metalloproteinases (MMPs), which are essential for osteoclast function and bone remodeling, have emerged as a key pathogenic pathway in FD. Lesion profiling revealed elevated expression of MMP-9, -13, and -14 in osteoclast-rich FD lesions, with dynamic regulation in response to pharmacologic RANKL inhibition and withdrawal. We hypothesized that MMPs may serve as lesion-associated biological cues for localized drug delivery in FD. We developed an injectable, sustained, and MMP-responsive local drug delivery system by integrating triglycerol monostearate nanoparticles within a dynamically crosslinked hyaluronic acid-based hydrogel scaffold (HPD/TGMS). To validate this strategy, the small-molecule RANKL inhibitor AS2676293 was loaded into TGMS to generate HPD/TGMS@A. Matrix metalloproteinase-mediated cleavage of the ester linkage in TGMS enabled protease-responsive drug release, further regulated by hydrogel-constrained perilesional retention. HPD/TGMS@A demonstrated favorable injectability, self-healing behavior, cytocompatibility, and MMP-dependent anti-osteoclastic activity in vitro. HPD/TGMS@A significantly attenuated FD lesion progression and improved bone microarchitecture in a GNASR201C knock-in FD mouse model through perilesional injection. Altogether, these findings establish HPD/TGMS as a localized, lesion-responsive drug delivery strategy in FD.Keywords
Funding Information
- National Regional Joint Key Fund (U24A20712)
- Sichuan University internal grants (23H0924)
- National Natural Science Foundation of China (82470940)
- National Natural Science Foundation of China (82371002)
- National Natural Science Foundation of China (82571136)
- National Natural Science Foundation of China (82330029)
- National Natural Science Foundation of China (2024NSFSC0540)
- National Natural Science Foundation of China (2025NSFCTD0026)
This publication has 33 references indexed in Scilit:
- ROS-triggered biomimetic hydrogel soft scaffold for ischemic stroke repairBiomaterials, 2025
- RANKL inhibition halts lesion progression and promotes bone remineralization in mice with fibrous dysplasiaBone, 2022
- Risk of Osteonecrosis of the Jaw Under Denosumab Compared to Bisphosphonates in Patients With OsteoporosisJournal of Bone and Mineral Research, 2020
- RANKL Inhibition in Fibrous Dysplasia of Bone: A Preclinical Study in a Mouse Model of the Human DiseaseJournal of Bone and Mineral Research, 2019
- Activation of RANK/RANKL/OPG Pathway Is Involved in the Pathophysiology of Fibrous Dysplasia and Associated With Disease BurdenJournal of Bone and Mineral Research, 2018
- Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its ExtensionJournal of Bone and Mineral Research, 2017
- Visual in vivo degradation of injectable hydrogel by real-time and non-invasive tracking using carbon nanodots as fluorescent indicatorBiomaterials, 2017
- Hypercalcemia after discontinuation of long-term denosumab treatmentOsteoporosis International, 2016
- Orally available pyridinylpyrimidine derivatives as novel RANKL-induced osteoclastogenesis inhibitorsBioorganic & Medicinal Chemistry Letters, 2012
- Matrix Metalloproteinases and Lysosomal Cysteine Proteases in Osteoclasts Contribute to Bone Resorption through Distinct Modes of ActionBiochemical and Biophysical Research Communications, 1999